Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript [Seeking Alpha]
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Minerva Neurosciences (NASDAQ:NERV) was downgraded by analysts at
Wall S
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors